Company intelligence / Profile preview

Ténor Formation

Ownership: Private
Development stage: Other

Overview

Formation Bio accelerates clinical-stage drug development using proprietary technology and AI to run trials faster and more efficiently than industry benchmarks. They have demonstrated trial startup and closeout timelines 2–3x faster than industry norms and patient recruitment up to 2.5x faster as of late 2024. Their model focuses on acquiring or licensing promising assets from pharma/biotech/universities and advancing them through proof-of-concept or later clinical milestones for value inflection. Specific clinical results for individual programs are not publicly disclosed.

Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Novartis (clinical trial site partnership)Pfizer (clinical trial speed/access partnership)Sanofi (as client when operating as CRO)Versanis Bio & Aditum Bio (as clients when operating as CRO)

Beyond the preview

Go deeper on Ténor Formation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ténor Formation.

Explore the full profile